Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a tablet game sharpen aging minds during breast cancer treatment?

NCT ID NCT04261153

Symptom relief Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This study explores whether a tablet-based cognitive stimulation program called HAPPYNeuron® is practical for breast cancer patients aged 70 and older. Cancer treatments, especially chemotherapy, can cause memory and thinking problems, and older patients may be at higher risk. The study will have participants complete three 20-minute sessions on a tablet to see if they can and will use the software, aiming to find a way to help reduce cognitive side effects and improve quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HAPPYNeuron® cognitive stimulation software
What this could lead to
If successful, this could point toward a practical, non-drug way to help older breast cancer patients maintain memory and thinking skills during cancer treatment.
What could go wrong
This is a small feasibility study, so it cannot prove the software improves cognition. Older patients may find tablet use difficult, and the program may not be widely adopted.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jun 2020

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient with breast cancer, aged 70 and over, * During treatment with chemotherapy, targeted therapy or radiotherapy. * Whatever the stage of the disease, * Hospitalised in a week hospital, in traditional hospitalisation for an intercurrent episode or day hospitalisation, or undergoing radiotherapy * Absence of major cognitive impairment preventing cognitive tests (compliance with the MoCA score threshold based on the patient's age and educational level according to GRECOGVASC standards), * Patient with education level 3 "end of primary education" minimum (Barbizet scale), * Mastery of the French language, * Patient who signed the consent to participate in the study. Exclusion Criteria: * Hospitalization for neurological reasons (e.g. confusion), or psychiatric, * Documented brain metastases, * History of brain radiation therapy, * Progressive psychiatric pathology or known dementia, * Abuse of alcohol or drug use, * Severe visual and / or hearing loss, * Patient's refusal to participate, * Patient deprived of liberty or under guardianship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Henri Becquerel

    Rouen, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.